echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Pfizer's third-generation ALK inhibitor and Cinda Bio-FGFR inhibitor are planned to be included in the priority review in China

    Pfizer's third-generation ALK inhibitor and Cinda Bio-FGFR inhibitor are planned to be included in the priority review in China

    • Last Update: 2021-08-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Finishingrainbow

    On July 12, the latest announcement by CDE showed that Pfizer's third-generation ALK inhibitor lorlatinib tablets and Cinda Bio's FGFR inhibitor pemigatinib tablets are planned to be included in the priority review


    Screenshot from CDE official website

    Pfizer lorlatinib

    Pfizer lorlatinib

    The CDE announcement showed that two applications of Pfizer's lorlatinib tablets (loratinib) have been included in the proposed priority review, and the proposed indications are: for the treatment of one or more ALK tyrosine kinase inhibitors in the past Of ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) patients


    Screenshot from CDE official website

    In NSCLC, anaplastic lymphoma kinase (ALK)-positive patients account for about 3%-5%


    Lorlatinib (Lorbrena) is a third-generation ALK inhibitor that has shown high activity in preclinical lung cancer models carrying ALK rearrangement


    It is reported that in the Phase II clinical trial of lorlatinib in the treatment of ALK+ or ROS1+ advanced NSCLC patients, for newly treated ALK-positive non-small cell lung cancer patients, the objective remission rate reached 90%, and the disease control rate reached 97%; Lorlatinib second-line or third-line treatment 59 For patients who have used crizotinib or crizotinib + chemotherapy, the objective response rate was as high as 69%


    Lorlatinib is to Pfizer, just like osimertinib is to AstraZeneca, it is used as a second-line therapy to provide a solution for patients to develop resistance to the first-generation drug, and then promoted to a first-line therapy to cover more patients The crowd


    Cinda Bio-pemigatinib

    Cinda Bio-pemigatinib

    CDE publicity shows that Cinda Bio FGFR 1/2/3 inhibitor pemigatinib tablets are planned to be included in the priority review.


    Screenshot from CDE official website

    Cholangiocarcinoma (CCA) is a malignant tumor that originates from bile duct epithelial cells.


    Innovent's pemigatinib is a selective fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor


    It is reported that pemigatinib is jointly developed by Incyte and Cinda Bio, and Cinda Bio is responsible for the commercialization of China, Hong Kong, Macau and Taiwan


    It is worth mentioning that, not long ago, Innovent has announced that the China Food and Drug Administration has accepted the marketing application of pemigatinib for this bile duct cancer indication


    A total of 108 patients with cholangiocarcinoma were enrolled in the FIGHT-202 study and received pemigatinib 13.


    Reference source: Medical Rubik's Cube, Insight database, Cinda Bio's official website

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.